Richard Marais | |
---|---|
Born | Richard Malcolm Marais |
Alma mater | University College London (BSc) Imperial College London (PhD) [1] |
Awards |
|
Scientific career | |
Fields | |
Institutions | |
Thesis | Comparative studies on protein kinase C isotypes (1989) |
Doctoral advisor | Peter Parker [1] [6] |
Other academic advisors | Richard Treisman Chris Marshall [6] |
Website | www |
Richard Malcolm Marais FRS FMedSci MAE [3] [7] [8] is Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester. [3] [9]
Marais was educated at University College London where he was awarded a Bachelor of Science degree in Genetics and Microbiology in 1985. [10] He completed his postgraduate study at the Ludwig Institute for Cancer Research and was awarded a PhD in 1989 for research on isotypes of the protein kinase C (PKC) enzyme supervised by Peter Parker. [1]
Marais's research investigates the biology of melanoma and other cancers in order to deliver better treatment strategies for patients. [3] [9] [5] [4] His studies on B-RAF [4] and cell signalling significantly advanced understanding of melanoma biology and aetiology. [3] [11] He translated his basic research discoveries into clinical implementation, improving patient outcomes, elucidating mechanisms of drug resistance and developing new drugs against BRAF and other cancer targets. [3] His research informs innovative clinical trial designs with signal-seeking biomarkers to monitor therapy responses and optimise patient treatment. [3] His research also highlights the importance of combining sunscreen with other sun avoidance strategies to reduce population melanoma risk. [3]
Marais started his career as a postdoctoral researcher with Richard Treisman [6] at the Imperial Cancer Research Fund (ICRF) in London, where he worked on the oncogene known as c-Fos. [8] This was followed by a period in Chris Marshall’s laboratory at the Institute of Cancer Research (ICR), after which Marais set up his own laboratory in 1998 before moving to Manchester in 2012. [6]
University of Manchester launched in 2019 an investigation into research misconduct from the Marais laboratory [12]
With colleagues, Marais received the American Association for Cancer Research (AACR) Team Science Award in 2012 for cancer drug discoveries. [3] He received the Leopold Griffuel Prize in 2016 [3] and the Outstanding Research Award from the Society for Melanoma Research (SMR) in 2017. [3] He was elected a member of the European Molecular Biology Organization (EMBO) in 2009, [2] a Fellow of the Royal Society (FRS) in 2018, [3] and a Fellow of the Academy of Medical Sciences (FMedSci) in 2008. [7] His citation on election reads:
Richard Marais is Professor of Molecular Oncology at Cancer Research UK and has made important contributions to the understanding of cell signalling pathways, particularly in cancer. He was amongst the first to show that mitogen activated protein kinases regulate gene expression by directly phosphorylating transcription factors. However his greatest impact has been with the RAF kinase family, where he discovered that individual RAF proteins are regulated differentially and shown how they respond to RAS, which is mutated in a third of all human tumours. He was a key member of the team that demonstrated that B-RAF is encoded by an oncogene, which is a culprit in most human melanomas. He went on to validate B-RAF as a therapeutic target. In collaboration with David Barford, he solved the crystal structure of B-RAF and explained how it is activated by mutations that occur in cancer. He elucidated why C-RAF is not mutated in cancer, showing that mutant forms of B-RAF can activate C-RAF through a novel mechanism, establishing a new paradigm of RAF signaling. He is now translating these studies to the clinic by leading a large effort to design and synthesize new anti-B-RAF drugs that will be used to treat melanoma. [7]
Marais was awarded membership of the Academia Europaea (MAE) in 2015. [8]
An oncogene is a gene that has the potential to cause cancer. In tumor cells, these genes are often mutated, or expressed at high levels.
The Institute of Cancer Research is a public research institute and a member institution of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.
RAF proto-oncogene serine/threonine-protein kinase, also known as proto-oncogene c-RAF or simply c-Raf or even Raf-1, is an enzyme that in humans is encoded by the RAF1 gene. The c-Raf protein is part of the ERK1/2 pathway as a MAP kinase (MAP3K) that functions downstream of the Ras subfamily of membrane associated GTPases. C-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases, from the TKL (Tyrosine-kinase-like) group of kinases.
Microphthalmia-associated transcription factor also known as class E basic helix-loop-helix protein 32 or bHLHe32 is a protein that in humans is encoded by the MITF gene.
Serine/threonine-protein kinase PAK 1 is an enzyme that in humans is encoded by the PAK1 gene.
BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf.
Dual specificity mitogen-activated protein kinase kinase 5 is an enzyme that in humans is encoded by the MAP2K5 gene.
Christopher John Marshall FRS FMedSci was a British scientist who worked as director of the Division for Cancer Biology at the Institute of Cancer Research. Marshall was distinguished for research in the field of tumour cell signalling. His track record includes the discovery of the N-Ras oncogene , the identification of farnesylation of Ras proteins, and the discovery that Ras signals through the MAPK/ERK pathway. These findings have led to therapeutic development of inhibitors of Ras farnesylation, MEK and B-Raf.
Vemurafenib (INN), sold under the brand name Zelboraf, is a medication used for the treatment of late-stage melanoma. It is an inhibitor of the B-Raf enzyme and was developed by Plexxikon.
David Julian Harry Downward FRS FMedSci is Associate Research Director at the Francis Crick Institute and Senior Group Leader at the Institute of Cancer Research. He was formerly head of the Signal transduction Laboratory at the London Research Institute. He is a member of the Editorial Board for Cell.
Encorafenib, sold under the brand name Braftovi, is a medication for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers. The substance was being developed by Novartis and then by Array BioPharma. In June 2018, it was approved by the FDA in combination with binimetinib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.
Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers. In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, it was approved by the FDA for treatment of NSCLC with a BRAF V600E mutation in combination with encorafenib. It was developed by Array Biopharma.
Jonathon Noë Joseph Pines is Head of the Cancer Biology Division at the Institute of Cancer Research in London. He was formerly a senior group leader at the Gurdon Institute at the University of Cambridge.
Anne Jacqueline Ridley is professor of Cell Biology and Head of School for Cellular and Molecular Medicine at the University of Bristol. She was previously a professor at King's College London.
James Briscoe is a senior group leader at the Francis Crick Institute in London and editor-in-chief of the journal Development.
Roger Lee Williams is a structural biologist and group leader at the Medical Research Council (MRC) Laboratory of Molecular Biology. His group studies the form and flexibility of protein complexes that associate with and modify lipid cell membranes. His work concerns the biochemistry, structures and dynamics of these key enzyme complexes.
Sir Richard Henry Treisman is a British scientist specialising in the molecular biology of cancer. Treisman is a director of research at the Francis Crick Institute in London.
Vassilis Pachnis Greek: Βασίλης Πάχνης is a Senior Group Leader in the Development and Homeostasis of the Nervous System Laboratory at the Francis Crick Institute.
(Robert) Charles Swanton is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.
Catrin Pritchard is a British researcher who is professor of cancer biochemistry and deputy director of the Leicester Cancer Research Centre at the University of Leicester. She was director of the Leicester CRUK Centre from 2014–2017 and head of department of cancer studies at the University of Leicester from 2014–2018. Her research focuses on animal and human preclinical models for cancer.
“All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --Royal Society Terms, conditions and policies at the Wayback Machine (archived 2016-11-11)
{{cite web}}
: CS1 maint: multiple names: authors list (link)This article incorporates text available under the CC BY 4.0 license.